Jim Simons’s Alder Biopharmaceuticals ALDR Stock Holding History

Jim Simons’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-101,500	Closed	-$1.69M	–	3757
2018 Q3	$1.69M	Sell	101,500 -333,300	-77%	-$6.02M	﹤0.01%	2359
2018 Q2	$6.87M	Buy	434,800 +112,500	+35%	+$1.71M	0.01%	1575
2018 Q1	$4.09M	Buy	+322,300	New	+$4.66M	﹤0.01%	1939
2016 Q2	–	Sell	-26,600	Closed	-$651K	–	3610
2016 Q1	$651K	Buy	+26,600	New	+$616K	﹤0.01%	2760
2015 Q3	–	Sell	-118,300	Closed	-$6.27M	–	3475
2015 Q2	$6.27M	Buy	+118,300	New	+$4.3M	0.01%	1296

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's ALDR Position: Q4 2018 in Review

Jim Simons sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 101,500 shares — an estimated $1.69M sold.

Jim Simons first reported a position in ALDR in Q2 2015 and held it in 5 quarters. The position peaked at $6.87M in Q2 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

Jim Simons reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Jim Simons sold 101,500 Alder Biopharmaceuticals shares in Q4 2018, an estimated $1.69M.
Jim Simons first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 5 quarters.
Jim Simons's Alder Biopharmaceuticals position peaked at $6.87M in Q2 2018.
124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Renaissance Technologies's 13F filing for Q4 2018, filed 13 Feb 2019.